The Effectiveness of Decametoxinum Inhalations in Patients with Bronchiectasis

Gashynova, K. and Suska, K. and Dmytrychenko, V. (2021) The Effectiveness of Decametoxinum Inhalations in Patients with Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 203. A3946. ISSN 1073-449X (Print); 1535-4970 (Online)

Text The Effectiveness of Decametoxinum Inhalations in Patients with.pdf Download (26kB)

Abstract

Bronchiectasis (Bx) is a chronic inflammatory lung disease characterized by recurrent cough, sputumproduction, and recurrent airway infections. The study aimed to determine lung microbiota composition in stablepatients with Bx and the effect of Decametoxinum (DECASAN®) Inhalations on it. Methods. The study includedstable patients with confirmed by HRCT Bx. Isolation and identification of pathogens was conducted bybacteriological methods. Inhalations of DECASAN® (0.8 mg) through nebulizer were carried out twice a day for14 days. Sputum samples were studied on the baseline (V1) and after 14 days of treatment (V2). The methodsof descriptive statistics and non-parametric statistics were used to process the results. Results. 80 patientswere examined. The average age was 53.2 (13.9) years, 28 of them were men (35%). Pathogens were detectedin 45 (56%) samples (s), the combination of pathogens - in ten (12.5%) patients. Pseudomonas aeruginosa (PA)was identified in 17 (21.3%)s. Among the pathogens identified in the remaining 28 patients were: Haemophilusinfluenza - in 18 s (22.5%), Candida albicans - in four patients (5%), Staphylococcus aureus - in three patients(3.8%), Streptococcus pneumoniae - in two patients (2.5%), Klebsiella pneumoniae - in one patient (1.3%), NFgram negative bacilli - in one patient (1.3%), Aspergillus niger - in one patient (1.3%). Nebulized inhalations ofDECASAN® received 28 patients, patients without sputum colonization (n=35) and patients colonized by PA(n=17) were excluded. Their median bacterial load at the beginning of the treatment was 7 log10 CFU*g-1 (5;8.1). After treatment the median bacterial load was 4 log10 CFU*g-1 (0; 5.5), the reduction in total sputumbacterial load was statistically significant (p=0.002 by the Wilcoxon test). Eradication occurred in 11 out of 28subjects (39.3 %), among them Haemophilus influenza was in 6 patients, Aspergillus niger in one patient,Klebsiella pneumoniae in one patient, Candida albicans in two patients, Streptococcus pneumoniae in one patient.No abnormal safety results and cases of bronchospasm were reported. Conclusions. PA and Haemophilusinfluenza are the most common pathogens in sputum of the patients with bronchiectasis in Ukraine whichcorresponds to the world data. Inhalations of antimicrobial drug DECASAN® through nebulizer showedeffectiveness in sputum bacterial load reduction in patients colonized by non-PA pathogens and could be aperspective therapeutic opportunity.

Item Type:	Article
Uncontrolled Keywords:	bronchiectasis, inhalations
Subjects:	Pulmonology
Divisions:	Departments > Department of occupational diseases, clinical immunology and clinical pharmacology
Depositing User:	Елена Шрамко
Date Deposited:	18 Nov 2021 09:29
Last Modified:	18 Nov 2021 09:29
URI:	http://repo.dma.dp.ua/id/eprint/7133

Actions (login required)

View Item